Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Health & wellness/
  4. Made in the shade: A new study looks at why a beach umbrella and high SPF sunscreen could be a good combo
JAMA Sunscreen Image

Made in the shade: A new study looks at why a beach umbrella and high SPF sunscreen could be a good combo

Have these dark and dreary winter days inspired you to plan a trip to the Caribbean? Before you make a beeline for that beach umbrella, don’t forget to apply some high SPF sunscreen.

According to a Johnson & Johnson study recently published in JAMA Dermatology, researchers found that sitting in the shade alone doesn’t adequately protect your skin from the sun’s harmful UV rays. Study participants who spent 3.5 hours on a sunny beach were divided into two groups: One sat under a beach umbrella with no other sun protection; the other applied SPF 100+ sunscreen, without any umbrella coverage.

Afterwards, 78% of people in the umbrella group showed signs of sunburn versus just 25% in the sunscreen group, suggesting that the sunscreen offered significantly better protection.

“Umbrella shade alone may not provide sufficient protection for extended sun exposure,” says the study’s lead author Hao Ou-Yang, Ph.D., Manager, Medical Research, R&D Fellow, Johnson & Johnson. “Although using SPF 100 was better than simply sitting in the shade, neither prevents sunburn completely. That’s why it’s essential to use a combination of sun protection methods.”

So when you get to the beach (or sit outside anywhere on a bright day), opt for multiple forms of protection—such as sunscreen, shade and hats—and then crack open a novel and order that fruity drink.

More from Johnson & Johnson

5 things we now know about bladder cancer

Paradigm-shifting new therapies are helping people with the disease lead longer, more comfortable lives. Learn how Johnson & Johnson is helping to change the treatment landscape.

What are alloantibodies?

Learn how Johnson & Johnson is investigating a therapy for two alloantibody-driven diseases that can affect the lives of developing fetuses and newborn babies.

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 56 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.